Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30603031 | 1.00 | KDM4E (0.44) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL3381245 | 0.85 | KDM4E (0.49) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL31266449 | 0.77 | KMT2A (0.53) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL9189341 | 0.77 | KDM4E (0.49) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL1396177 | 0.75 | PLAU (0.47) | KDM4EMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL10159159 | 0.74 | KDM4E (0.61) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL29980123 | 0.74 | KDM4E (0.61) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL12070663 | 0.73 | TOP1 (0.42) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL26627513 | 0.73 | NSD2 (0.45) | KDM4EHSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL196848 | 0.73 | KMT2A (0.68) | KDM4EHSP90AA1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3873605-A1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-112969504-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | KDM4E 2712/4885HSP90AA1 2146/4885MAPT 2845/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | KDM4E 1442/4885HSP90AA1 1344/4885MAPT 3224/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | KDM4E 1209/4885HSP90AA1 1972/4885MAPT 3196/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | KDM4E 1442/4885HSP90AA1 1344/4885MAPT 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.